Newer insulin analogues and inhaled insulin

Indian Journal of Medical Sciences

Volumn 60, Issue 3, 2006, Pages 117-123

  Girish, C ^a   Manikandan, S ^a   Jayanthi, M ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Albulin; Diabetes; Inhaled insulin; Insulin detemir; Insulin glulisine

Indexed keywords

ALBULIN; GLUCOSE; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR SUBSTRATE 2; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AUTOIMMUNITY; CARCINOGENIC ACTIVITY; COUGHING; DIABETES CONTROL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSPNEA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; REVIEW; SORE THROAT; XEROSTOMIA;

EID: 33645565570     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.22765     Document Type: Review

References (20)

1. World Health Organization home page: health topics: diabetes: Assessed on 8-2-2005, http://www.who.int/diabetes/facts/world_figures/en/
2. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
3. Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004;26:445-61.
4. Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action. Biochem Biophys Res Commun 2003;310:852-9.
5. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, et al. A novel insulin analog with unique properties, LysB3, GluB29 insulin induces prominent activation of insulin receptor substrate-2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 2003;52:2227-38.
6. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.
7. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabet Care 2001;24:296-301.
8. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996;85:304-8
9. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabet Care 2003;26:590-6.
10. Danne T, Lupke K, Walte K, Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents and adults with type 1 diabetes. Diabet Care 2003;26:3087-92.
11. Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 1997;86:1365-8.
12. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabet Care 2004;27:1081-7.
13. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, et al. Development of a long acting insulin analogue using albumin fusion technology. Diabetes 2005;54:251-8.
14. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2005;62:1359-64.
15. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209.
16. Valente AX, Langer R, Stone HA, Edwards DA. Recent Advances in the Development of an Inhaled Insulin Product. Biodrugs 2003;17:9-17.
17. Moses AC, Gordon GS, Carey MC, Flier JS. Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects. Diabetes 1983;32:1040-7.
18. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003;20:886-98.
19. Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabet Care 2002;25:2276-81.
20. FDA home page. Assessed on 8-2-2006: www.fda.gov,http://www. drugdevelopment-technology.com/projects/exubera/